Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

(2020) Elisabeth H. Thijssen et al.   NATURE MEDICINE

Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography

(2020) Pierre-François Meyer et al.   JAMA Neurology

Age‐dependent amyloid deposition is associated with white matter alterations in cognitively normal adults during the adult life span

(2020) Miguel Á. Araque Caballero et al.   Alzheimers & Dementia

Temporal trajectories of in vivo tau and amyloid-β accumulation in Alzheimer’s disease

(2020) Min Seok Baek et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

(2020) Thomas K Karikari et al.   LANCET NEUROLOGY

The transformative potential of plasma phosphorylated tau

(2020) Clifford R Jack   LANCET NEUROLOGY

An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders

(2020) Nicholas J. Ashton et al.   Nature Reviews Neurology

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease

(2020) Niklas Mattsson-Carlgren et al.   Science Advances

Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline

(2020) Juan Lantero Rodriguez et al.   ACTA NEUROPATHOLOGICA

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

(2020) Sebastian Palmqvist et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease

(2020) Nicolas R. Barthélemy et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration

(2020) Alberto Benussi et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study

(2020) Antoinette O’Connor et al.   MOLECULAR PSYCHIATRY

White matter hyperintensities are associated with subthreshold amyloid accumulation

(2020) Alexis Moscoso et al.   NEUROIMAGE

A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease

(2019) Nicholas J. Ashton et al.   Science Advances

Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease

(2019) Andrea Vergallo et al.   Alzheimers & Dementia

Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia

(2019) Gil D. Rabinovici et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease

(2019) Niklas Mattsson et al.   JAMA Neurology

White matter hyperintensities: relationship to amyloid and tau burden

(2019) Jonathan Graff-Radford et al.   BRAIN

Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease

(2019) Bernard J. Hanseeuw et al.   JAMA Neurology

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

(2019) Sebastian Palmqvist et al.   EMBO Molecular Medicine

Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays

(2019) Kaj Blennow et al.   Scientific Reports

Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging

(2018) Suzanne E. Schindler et al.   Alzheimers & Dementia

Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography

(2018) Michelle M. Mielke et al.   Alzheimers & Dementia

PET staging of amyloidosis using striatum

(2018) Bernard J. Hanseeuw et al.   Alzheimers & Dementia

CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts

(2018) Oskar Hansson et al.   Alzheimers & Dementia

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

Tau-targeting therapies for Alzheimer disease

(2018) Erin E. Congdon et al.   Nature Reviews Neurology

Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology

(2018) Renaud La Joie et al.   Alzheimers & Dementia

Blood-based biomarkers for Alzheimer’s disease—An update

(2018) Henrik Zetterberg   JOURNAL OF NEUROSCIENCE METHODS

Biomarkers for tau pathology

(2018) Michael Schöll et al.   MOLECULAR AND CELLULAR NEUROSCIENCE

PETPVE12: an SPM toolbox for Partial Volume Effects correction in brain PET – Application to amyloid imaging with AV45-PET

(2017) Gabriel Gonzalez-Escamilla et al.   NEUROIMAGE

Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease

(2017) Anne Maass et al.   NEUROIMAGE

In vivo staging of regional amyloid deposition

(2017) Michel J. Grothe et al.   NEUROLOGY

Constructing longitudinal disease progression curves using sparse, short-term individual data with an application to Alzheimer's disease

(2017) C.A. Budgeon et al.   STATISTICS IN MEDICINE

Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity

(2017) Sebastian Palmqvist et al.   Nature Communications

Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging

(2017) Michelle M. Mielke et al.   JAMA Neurology

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease

(2017) Niklas Mattsson et al.   JAMA Neurology

Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid

(2016) Tobias Bittner et al.   Alzheimers & Dementia

Plasma tau in Alzheimer disease

(2016) Niklas Mattsson et al.   NEUROLOGY

PET Imaging of Tau Deposition in the Aging Human Brain

(2016) Michael Schöll et al.   NEURON

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease

(2016) Matthew R. Brier et al.   Science Translational Medicine

The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015

(2015) William J. Jagust et al.   Alzheimers & Dementia

The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET

(2015) William E. Klunk et al.   Alzheimers & Dementia

The Alzheimer’s Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans

(2015) Ju-Hee Kang et al.   Alzheimers & Dementia

Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2

(2015) Clifford R. Jack et al.   Alzheimers & Dementia

Tau positron emission tomographic imaging in aging and early Alzheimer disease

(2015) Keith A. Johnson et al.   ANNALS OF NEUROLOGY

Amyloid biomarkers in Alzheimer's disease

(2015) Kaj Blennow et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

The A4 Study: Stopping AD Before Symptoms Begin?

(2014) R. A. Sperling et al.   Science Translational Medicine

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

(2013) Victor L Villemagne et al.   LANCET NEUROLOGY

Brain  -amyloid load approaches a plateau

(2013) C. R. Jack et al.   NEUROLOGY

National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

(2012) Bradley T. Hyman et al.   Alzheimers & Dementia

Amyloid-  Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods

(2012) S. M. Landau et al.   JOURNAL OF NUCLEAR MEDICINE

Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease

(2011) Victor L. Villemagne et al.   ANNALS OF NEUROLOGY

The importance of appropriate partial volume correction for PET quantification in Alzheimer’s disease

(2011) Benjamin A. Thomas et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Soluble amyloid  -protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration

(2011) M. Jin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization

(2009) R. C. Petersen et al.   NEUROLOGY

Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers

(2007) Fernanda G. De Felice et al.   NEUROBIOLOGY OF AGING